Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 2;10:5492. doi: 10.1038/s41467-019-13420-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — Low expression of Elongator/hnRNPQ/P53 is correlated with poor gemcitabine sensitivity and poor survival outcomes in GBC patients. a ELP5, hnRNPQ, and P53 expression assessed by histoscore were negatively correlated with the proliferation rate of GBC primary tumor cells under GEM treatment in mini-PDX models (Cohort 1), as normalized to vehicle treatment. Data represent the mean ± S.D, error bars represent S.D. b Kaplan–Meier estimate of survival time in GBC patients who received gemcitabine-cisplatin therapy after surgery (Cohort 2) according to different ELP5, hnRNPQ, and P53 levels in paraffin-fixed tumorous specimens. Scale bars = 100 μm. c, d Univariate (c) and multivariate (d) Cox regression analyses were performed in Cohort 2. The bars represent 95% CI. CI, confidence interval; HR, hazard ratio. e Kaplan–Meier estimate of survival time in GBC patients who received gemcitabine-cisplatin therapy after surgery (Cohort 2) based on combined ELP5 and T stages: low risk (high ELP5 and early T stage), intermediate-risk (low ELP5 and early T stage, or high ELP5 and advanced T stage), and high-risk (low ELP5 and advanced T stage) groups. Early T stage, T_1~2; advanced T stage, T_3~4. Mann–Whitney U tests were used in a (upper panel), the Pearson correlation coefficient were used in a (down panel), and log-rank tests were used in b, e.